吉西他滨或多西他赛联合顺铂化疗治疗NSCLC对患者凝血功能 CYFRA21-1 CA199的影响

doi:10.3969/j.issn.1006-6233.2021.09.036

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1227 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the effects of gemcitabine or docetaxel combined with cisplatin chemotherapy in the treatment of non-small cell lung cancer (NSCLC) on the blood coagulation function, soluble fragments of cytokeratin 19 (CYFRA21-1), and carbohydrate antigen 199 (CA199). Methods: We retrospectively analyzed the case data of 104 patients with advanced NSCLC who underwent radiotherapy in the oncology department of our hospital from January 2019 to January 2020. According to the chemotherapy regimen, NSCLC was divided into 2 groups, GP group (gemcitabine combined with cisplatin) of 54 cases, and DP group (docetaxel combined with cisplatin) of 50 cases. Comparison of the effects of chemotherapy was conducted between the two groups concerning the coagulation function before and after chemotherapy [thrombin time (TT), activated partial thromboplastin time (APTT), platelets (PLT), prothrombin time (PT), fibrinogen (FIB), plasma D -Dimer (DD)], CYFRA21-1, CA199 levels, and toxic side effects. Results: The tumor control rates of GP group and DP group were 83.33% and 78.00%, respectively, and the difference was not statistically significant (P>0.05). Repeated measures analysis of variance showed that the difference between FIB before and after treatment was statistically significant (P<0.05), but the difference between groups was not statistically significant (P>0.05); the interaction between time and treatment has an effect on TT and PLT Statistically significant (P<0.05), the difference between TT and PLT before and after treatment in the GP group was greater than that in the DP group. Repeated measures analysis of variance showed that CYFRA21-1 and CA199 were different before and after treatment (P<0.05), but there was no difference between different treatment methods, and the interaction between treatment methods and time was not statistically significant (P>0.05) ). The incidence of abnormal liver function and thrombocytopenia in the GP group was higher than that in the DP group, and the incidence of leukopenia and muscle soreness in the GP group was lower than that in the control group. The difference was statistically significant (P<0.05); The incidence of grade III-IV thrombocytopenia was higher than that of the DP group, and the incidence of grade I-IV leukopenia was lower than that of the control group, and the difference was statistically significant (P<0.05). In addition, most of the toxic and side effects are grade Ⅰ to II, which can basically be relieved by themselves, while grades III to IV are obviously relieved after symptomatic treatment. Conclusion: GP and DP chemotherapy regimens have similar effects in the treatment of NSCLC, and have little difference in the level of CYFRA21-1 and CA199. However, the effect of GP chemotherapy in improving blood hypercoagulability is more significant than that of DP chemotherapy, and the side effects of GP chemotherapy are thrombocytopenia Mainly, the DP chemotherapy regimen mainly focuses on leukopenia.

Key words： Mon-small cell lung cancer Gemcitabine Docetaxel Cisplatin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Lijun
	TAN Shiyun
	LIU Xuchu
	et al

Cite this article:

CHEN Lijun,TAN Shiyun,LIU Xuchu, et al. Effect of Brucea Javanica Oil Emulsion Injection Combined with NP Chemotherapy on Immune Function Coagulation and Pulmonary Function in Patients with Lung Cancer[J]. HeBei Med, 2021, 27(9): 1566-1571.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.09.036 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I9/1566

[1] B W C A,D Q Y C,E Z Y,et al.Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest[J].Biochemical and Biophysical Research Communications,2020,524(3):549~554.
[2] 赵纪春,吴洲鹏,郭强.肿瘤相关静脉血栓栓塞症治疗指南解读[J].中国普外基础与临床杂志,2020,27(4):407~411.
[3] 张东伟,蓝冰.不同化疗药物治疗小细胞肺癌对患者预后及肿瘤标志物水平的影响[J].国际肿瘤学杂志,2019,46(10):585~589.
[4] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40(12):935~964.
[5] Eisenhauer E A, Therasse P, Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].European Journal of Cancer,2009,45(2):247.
[6] Rutten L J F,Blake K D,Skolnick V G,et al.Data resource profile:the national cancer institute's health information national trends survey (HINTS)[J].International Journal of Epidemiology,2020,49(1):17.
[7] 刘渭滨,葛明建,叶小叶,等.芦荟苷联合顺铂对非小细胞肺癌细胞的影响研究[J].中国临床药理学杂志,2020,36(2):56~59.
[8] 徐芹,鲍瑜,亢晓彬.多西他赛联合阿帕替尼二线治疗进展期非小细胞肺癌的临床效果[J].中国医药导报,2020,17(23):101~104.
[9] 廖明,徐志勇,彭丽君.吉西他滨联合顺铂对肺癌的临床治疗效果及安全性评估[J].药物评价研究,2019,42(10):117~120.
[10] 许洁,韩洪超,崇庆国,等.血浆D-二聚体及血小板水平检测在以VTE为早期表现的恶性肿瘤中的意义[J].中国医师杂志,2019,21(4):124~126.
[11] 胡梅叶,孟晓皓.多西他赛对比吉西他滨联合顺铂化疗对肺癌患者凝血状态的影响[J].实用癌症杂志,2017,32(12):1990~1992.